Elsevier

Clinical Therapeutics

Volume 30, Issue 7, July 2008, Pages 1228-1250
Clinical Therapeutics

New Drug
Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection

https://doi.org/10.1016/S0149-2918(08)80048-3Get rights and content

Abstract

Background: The emergence of viral resistance is one of the greatest challenges in the treatment of HIV infection. Maraviroc is the first member of a new class of antiretroviral medications, the CCR5-receptor antagonists. It is approved by the US Food and Drug Administration (FDA) for use in combination with other antiretroviral agents in treatment-experienced patients infected with multidrug-resistant, CCR5-tropic HIV-1.

Objective: This article provides an overview of the pharmacology, efficacy, and tolerability of maraviroc in the treatment of HIV-1 infection.

Methods: Relevant information was identified through a search of MEDLINE (January 2000-May 2008) using the terms maraviroc, UK-427,857, and CCR5-receptor antagonist. Also consulted were abstracts from the International AIDS Society Conference, the Conference on Retroviruses and Opportunistic Infections, and other relevant scientific meetings. Additional publications were found by searching the reference lists of the identified articles and the FDA Web site.

Results: Maraviroc is a selective, reversible, small-molecule CCR5-receptor antagonist. In vitro, it has potent anti-HIV-1 activity, with a mean 90% inhibitory concentration of 2.0 nmol/L. It is widely distributed, with a Vd of ~194 L. Maraviroc is moderately metabolized in the liver (65.3%), primarily via the cytochrome P450 3A4 isozyme. It has an elimination t1/2 of 15.9 to 22.9 hours. Until more data are available, maraviroc should be avoided in patients with severe hepatic insufficiency; dose adjustment does not appear to be necessary on the basis of age, sex, or renal function. In 2 Phase IIb/III studies, maraviroc 300 mg PO QD or BID was found to be more efficacious than placebo in reducing the viral load at 48 weeks in treatment-experienced, CCR5-tropic HIV-1-infected patients receiving an optimized background regimen (difference vs placebo—QD arm: -0.89 log10 copies/mL [97.5% CI, -1.17 to -0.62]; BID arm: -1.05 log10 copies/mL [97.5% CI, -1.33 to -0.78]). The proportion of patients with a viral load <50 copies/mL was 43.2% in the QD arm and 45.5% in the BID arm, compared with 16.7% in the placebo arm (P < 0.001, both treatment arms vs placebo). In treatment-naive patients infected with CCR5-tropic virus only, maraviroc 300 mg PO BID was not noninferior to oral efavirenz 600 mg QD (difference = -4.2%; lower bound of the 1-sided 97.5% CI, -10.9 [predefined statistical cutoff for noninferiority, -10]). Maraviroc was generally well tolerated in clinical trials. The most frequently reported (≥5%) adverse events were upper respiratory tract infection (20.0%), cough (12.7%), pyrexia (12.0%), rash (9.6%), musculoskeletal complaints (8.7%), gastrointestinal and abdominal pain (8.2%), dizziness (8.2%), appetite disorders (7.3%), insomnia (7.0%), herpes infection (6.8%), sinusitis (6.3%), joint complaints (6.1%), bronchitis (5.9%), and constipation (5.4%). The recommended dose of maraviroc differs based on concomitant medications, ranging from 150 to 600 mg BID.

Conclusion: When used in combination with other antiretroviral agents, maraviroc appears to be a promising agent for treatment-experienced patients infected with multidrug-resistant, CCR5-tropic HIV-1.

References (58)

  • RS Hogg et al.

    Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART

    PLoS Med.

    (2006)
  • M Marmor et al.

    Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection

    J Acquir Immune Defic Syndr

    (2001)
  • 2007 AIDS epidemic update [UNAIDS Web...
  • RM Gulick

    New antiretroviral drugs

    Clin Microbiol Infect

    (2003)
  • A Mocroft et al.

    Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: Results from the EuroSIDA Study Group

    J Infect Dis

    (2004)
  • KA Nagashima et al.

    Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion

    J Infect Dis

    (2001)
  • EA Berger et al.

    A new classification for HIV-1

    Nature

    (1998)
  • M Samson et al.

    Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

    Nature

    (1996)
  • R Liu et al.

    Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

    Cell

    (1996)
  • AM de Roda Husman et al.

    Association between CCR5 genotype and the clinical course of HIV-11 infection

    Ann Intern Med

    (1997)
  • J Wheeler et al.

    Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: Experience in a drug development programme for maraviroc

    Antivir Ther

    (2007)
  • JP Moore et al.

    The entry of entry inhibitors: A fusion of science and medicine

    Proc Natl Acad Sci U S A

    (2003)
  • JD Reeves et al.

    Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

    Proc Natl Acad Sci U S A

    (2002)
  • LA Cooley et al.

    HIV-1 cell entry and advances in viral entry inhibitor therapy

    J Clin Virol

    (2003)
  • N Cammack

    The potential for HIV fusion inhibition

    Curr Opin Infect Dis

    (2001)
  • RW Doms et al.

    The plasma membrane as a combat zone in the HIV battlefield

    Genes Dev

    (2000)
  • P Dorr et al.

    Maraviroc (UUK-427,857), a potent, orally bioavailable,and selective small-molecule inhibitor of chemokine receptor CCR5 with broadspectrum anti-human immunode-ficiency virus type 1 activity

    Antimi-crob Agents Chemother

    (2005)
  • NA Meanwell et al.

    Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS

    Curr Opin Investig Drugs

    (2007)
  • G Fätkenheuer et al.

    Efficacy of shortterm monotherapy with maraviroc, a new CCR5 ntagonist, n patients infected with HIV-1

    Nat Med

    (2005)
  • P Biswas et al.

    Access denied? The status of coreceptor inhibition to counter HIV entry

    Expert Opin Pharmacother

    (2007)
  • S Abel et al.

    Assessment of the pharmaco-kinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers

    Br J Clin Pharmacol

    (2008)
  • Dumond JB, Patterson KB, Pecha A, et al. Maraviroc pharmacokinetics in blood plasma, genital tract fluid and tissue in...
  • Lalezari J, Goodrich J, DeJesus E, et al, for the MOTIVATE 1 Study Team. Efficacy and safety of maraviroc in...
  • Fatkenheuer G, Konourina I, Nelson M, et al, for the MOTIVATE 2 Study Team. Efficacy and safety of maraviroc (MVC) plus...
  • DK Walker et al.

    Species differences in the disposition of the CCR5 antagonist, UK-4427,857, a new potential treatment for HIV

    Drug Metab Dispos

    (2005)
  • Maraviroc tablets NDA 22-128 [briefing document] [US Food and Drug Administration Web...
  • Hoepelman IM, Ayoub A, Heera J, et al. The incidence of severe liver enzyme abnormalities and hepatic adverse events in...
  • M Westby et al.

    Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bbound receptor for entry

    J Virol

    (2007)
  • Cited by (0)

    View full text